Chandana Mishra, MD
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1174626667
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,526 of the $11,300 with a category attached, or 66.6%. 40 manufacturers reported payments, led by Mannkind Corporation at 36.4% of the total. Reporting peaked in 2022 at $4,793 and has fallen 72.5% since, to $1,321 in 2025.
Across 340 payments — averaging $33.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$4K
- Amgen$832
- Corcept Therapeutics$738
- Lilly USA, LLC$690
- Abbott$484
- Rhythm Pharmaceuticals, Inc.$409
- plus $4K from 34 others
What the payments were for
- Consulting fees$1,70015%
- Travel & lodging$2,07518%
- Food & beverage$7,52667%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 24 | $4,109 |
| Amgen(2 entities) | 32 | $832 |
| Corcept Therapeutics | 14 | $738 |
| Lilly USA, LLC | 36 | $690 |
| Abbott | 44 | $484 |
| Rhythm Pharmaceuticals, Inc. | 5 | $409 |
| Dexcom, Inc. | 16 | $386 |
| Recordati_rare_diseases_inc. | 4 | $377 |
| Insulet Corporation | 15 | $367 |
| Boehringer Ingelheim | 15 | $353 |
| Novo Nordisk | 24 | $304 |
| BETA Bionics, Inc. | 22 | $291 |
| Sequel Med Tech, LLC | 3 | $279 |
| Sanofi-aventis U.S. LLC | 16 | $233 |
| AbbVie | 9 | $166 |
| Cequr Corporation | 2 | $105 |
| Medtronic(2 entities) | 4 | $104 |
| Chiesi USA, Inc. | 4 | $95 |
| Pfizer | 6 | $92 |
| AstraZeneca(2 entities) | 5 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Merck | 5 | $73 |
| Radius Health, Inc. | 3 | $71 |
| Novartis | 3 | $69 |
| Soleno Therapeutics, Inc. | 3 | $65 |
| Lifescan, Inc. | 3 | $64 |
| Tandem Diabetes Care, Inc. | 2 | $48 |
| Verity Pharmaceuticals Inc. | 2 | $46 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Johnson & Johnson | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $30 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Almatica Pharma LLC | 1 | $25 |
| Antares Pharma, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,300 in reported general payments places this provider in the 80th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $163,179 |
| JardianceEmpagliflozin | 67 | $105,229 |
| MounjaroTirzepatide | 51 | $62,434 |
| ForteoTeriparatide | 12 | $59,779 |
| TrulicityDulaglutide | 34 | $38,453 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $33,641 |
| GenotropinSomatropin | 13 | $23,787 |
| FarxigaDapagliflozin Propanediol | 18 | $23,660 |
| Teriparatide | 11 | $21,607 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $16,054 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $15,024 |
| SynthroidLevothyroxine Sodium | 152 | $14,138 |
| JanuviaSitagliptin Phosphate | 17 | $14,098 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $13,343 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 45 | $4,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $304 | $163,179123 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $690 | $160,66797 claims |
| Boehringer IngelheimJardiance | $353 | $105,22967 claims |
| MerckJanuvia, Janumet Xr | $73 | $27,44132 claims |
| PfizerGenotropin | $92 | $23,78713 claims |
| AstraZenecaFarxiga | $85 | $23,66018 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $233 | $15,02411 claims |
| AbbVieSynthroid | $166 | $14,138152 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $36 | $4,755460 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
- Mercedes RomeroScottsdale$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.